#
Kisqali Femara Co-Pack
  • Treatments
  • Breast Cancer
  • Kisqali Femara Co-Pack (Oral)

Kisqali Femara Co-Pack (Oral)

Generic name:ribociclib and letrozole (oral route) [ rye-boe-SYE-klib, LET-roe-zole ]
Drug class:Antineoplastic combinations

Medically reviewed by Drugs.com. Last updated on Apr 30, 2022.

Commonly used brand name(s)

In the U.S.

  • Kisqali Femara Co-Pack

Available Dosage Forms:

  • Tablet

Uses for Kisqali Femara Co-Pack

Ribociclib and letrozole combination is used to treat hormone receptor (HR)-positive, HER-2 negative advanced or metastatic (cancer that has spread) breast cancer in pre/perimenopausal women, postmenopausal women, or men.

Ribociclib belongs to the group of medicines called antineoplastics. It interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells may also be affected by the medicine, other unwanted effects will also occur. Some of these may be serious and must be reported to your doctor.

Some hormones that occur naturally in the body can increase the growth of some breast cancers. Letrozole works by decreasing the amounts of these hormones in the body.

This medicine is available only with your doctor's prescription.

Before using Kisqali Femara Co-Pack

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of ribociclib and letrozole combination in the pediatric population. Safety and efficacy have not been established.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-sp...